BBPOS
25.5.2016 10:01:37 CEST | Business Wire | Press release
BBPOS has announced the launch of WisePadTM 2; advanced technology developed by innovative engineers. The WisePadTM 2 can be used in an integrated or semi-integrated POS environment as well as a stand-alone environment connecting to the payment processor or gateway via GPRS, 3G or Wi-Fi.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160525005100/en/
WisePadTM 2 reads EMV chip card, triple track magnetic stripe card, NFC card and has a secured PIN pad. Compact and lightweight at 3.7oz (105g), it is mobile and flexible. The WisePadTM 2 also has standard over-the-air features allowing both firmware updates and key injection that are essential in increasing operational efficiency as well as having a 2G/3G modem to allow direct connectivity to the network.
WisePadTM 2 complies with all major industrial security standards including PCI PTS v4.1 with SRED; EMV L1 & L2; EMV Contactless L1; VISA payWave; MasterCard PayPass; AMEX ExpressPay; Discover D-PAS; and MasterCard TQM.
WisePadTM 2 will be widely adopted as a mobile solution working with a smart device or as a stand-alone solution. It will also be a good alternative to conventional counter-top POS devices in countries which use Chip and PIN payment systems, such as China and in Europe. The non-NFC versions have been used at a number of key events and by merchants. For example, at the Dubai World Cup, customers had the flexibility and convenience of not waiting in long queues to purchase tickets and, instead, were able to use their debit or credit cards via roaming staff who were using tablets and WisePadTM .
WisePadTM 2 is the future of mPOS - delivering a cost effective solution with convenient updating and a wide range of applications. Please visit our website for more details.
BBPOS
www.bbpos.com
WisePadTM
2
http://bbpos.com/files/bbproducts/11-WP2_A4_Catalogue_20160523.pdf
About BBPOS
Founded in 2008, BBPOS is an mPOS solution provider headquartered in Hong Kong with regional offices in San Jose, Miami, London, Singapore and Shanghai. The business invented the mobile payment audio jack at a time when smart phones were in their infancy. Today, we are respected as a leading innovator, designer, and manufacturer of end-to-end mobile POS solutions, serving key sectors including mobile merchant, retail, hospitality, delivery, transport and government.
Our world-class engineering team has developed a family of innovative POS devices that deliver quality solutions while implementing the highest security standards. Our products are designed with the flexibility to securely manage any transaction, in any environment, anywhere in the world. In March 2016, mPOS tracker ranked BBPOS 6th among 212 global payment industry players with a high score of 70.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160525005100/en/
Contact:
BBPOS
Gloria Chan, +852-3907-0305
gloria.chan@bbpos.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom